A Study of IBI362 in Participants With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL

Enrollment

731

Participants

Timeline

Start Date

January 6, 2023

Primary Completion Date

January 26, 2024

Study Completion Date

April 9, 2024

Conditions

Type 2 Diabetes

Interventions

DRUG

dulaglutide

Dulaglutide administered subcutaneously (SC) once a week.

DRUG

IBI362

IBI362 administered subcutaneously (SC) once a week.

Trial Locations (1)

China-Japan Friendship Hospital, Beijing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY